This study further investigates the similarity of QL1209 to reference pertuzumab in terms of efficacy and safety in the neoadjuvant treatment of early or locally advanced HER2-positive, ER/PR-negative breast cancer. This evidence concerns the gene ERBB2 and breast cancer.